Cue Biopharma (CUE) – Investment Analysts’ Weekly Ratings Updates

Cue Biopharma (NASDAQ: CUE) recently received a number of ratings updates from brokerages and research firms:

• 5/27/2026 – Cue Biopharma was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/19/2026 – Cue Biopharma was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/18/2026 – Cue Biopharma was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/11/2026 – Cue Biopharma was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/3/2026 – Cue Biopharma was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 4/25/2026 – Cue Biopharma was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 4/11/2026 – Cue Biopharma was upgraded by Wall Street Zen to “buy”.

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.